Harvard Bioscience shares rise 5.02% after-hours following appointment of Stephen DeNelsky to the Board of Directors.

Harvard Bioscience, Inc. rose 5.02% in after-hours trading, following the appointment of Stephen DeNelsky to its Board of Directors. DeNelsky, a Managing Director at Oaktree Capital Management, brings extensive experience in life sciences industry financing, which is expected to benefit the company's strategic direction and governance. The company's products and services are sold globally to customers ranging from renowned academic institutions and government laboratories to pharmaceutical, biotechnology, and contract research organizations (CROs).